文献速递临床试验与 GCP流行病学与生物统计

2型糖尿病患者强化血糖控制的15年随访

Intensive Glucose Control in Patients with Type 2 Diabetes - 15-Year Follow-up.
PubMed 文献 · N Engl J Med · 2019-01-01

对1791名2型糖尿病退伍军人进行强化与标准降糖治疗,中位5.6年干预期后观察性随访至15年。强化治疗组主要心血管事件风险在糖化血红蛋白曲线分离期间降低(HR 0.83),但曲线持平后无获益;15年总体主要心血管事件(HR 0.91)和死亡(HR 1.02)风险未降低。

要点

  • 强化降糖组在糖化血红蛋白曲线分离期间主要心血管事件风险降低(HR 0.83)。
  • 曲线持平后该获益消失(HR 1.26),无遗留效应。
  • 15年总体主要心血管事件和死亡风险未降低。

核心结论

  • 强化血糖控制仅在糖化血红蛋白曲线分离的延长期间降低主要心血管事件风险,无遗留效应或死亡获益。

研究设计与样本

  • 对1791名2型糖尿病退伍军人随机分组后完成原试验,随后通过中央数据库进行观察性随访,完整队列1655人,调查队列1391人。

主要发现

  • 原试验强化治疗组892人vs标准治疗组899人,糖化血红蛋白曲线平均分离1.5个百分点,试验结束后3年降至0.2至0.3个百分点。
  • 15年随访期间,主要心血管事件风险强化组vs标准组HR 0.91(95%CI 0.78-1.06,P=0.23),死亡风险HR 1.02(95%CI 0.88-1.18)。
  • 糖化血红蛋白曲线分离期间主要心血管事件风险HR 0.83(95%CI 0.70-0.99),曲线持平后HR 1.26(95%CI 0.90-1.75)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We previously reported that a median of 5.6 years of intensive as compared with standard glucose lowering in 1791 military veterans with type 2 diabetes resulted in a risk of major cardiovascular events that was significantly lower (by 17%) after a total of 10 years of combined intervention and observational follow-up. We now report the full 15-year follow-up. METHODS: We observationally followed enrolled participants (complete cohort) after the conclusion of the original clinical trial by using central databases to identify cardiovascular events, hospitalizations, and deaths. Participants were asked whether they would be willing to provide additional data by means of surveys and chart reviews (survey cohort). The prespecified primary outcome was a composite of major cardiovascular events, including nonfatal myocardial infarction, nonfatal stroke, new or worsening congestive heart failure, amputation for ischemic gangrene, and death from cardiovascular causes. Death from any cause was a prespecified secondary outcome. RESULTS: There were 1655 participants in the complete cohort and 1391 in the survey cohort. During the trial (which originally enrolled 1791 participants), the separation of the glycated hemoglobin curves between the intensive-therapy group (892 participants) and the standard-therapy group (899 participants) averaged 1.5 percentage points, and this difference declined to 0.2 to 0.3 percentage points by 3 years after the trial ended. Over a period of 15 years of follow-up (active treatment plus post-trial observation), the risks of major cardiovascular events or death were not lower in the intensive-therapy group than in the standard-therapy group (hazard ratio for primary outcome, 0.91; 95% confidence interval [CI], 0.78 to 1.06; P = 0.23; hazard ratio for death, 1.02; 95% CI, 0.88 to 1.18). The risk of major cardiovascular disease outcomes was reduced, however, during an extended interval of separation of the glycated hemoglobin curves (hazard ratio, 0.83; 95% CI, 0.70 to 0.99), but this benefit did not continue after equalization of the glycated hemoglobin levels (hazard ratio, 1.26; 95% CI, 0.90 to 1.75). CONCLUSIONS: Participants with type 2 diabetes who had been randomly assigned to intensive glucose control for 5.6 years had a lower risk of cardiovascular events than those who received standard therapy only during the prolonged period in which the glycated hemoglobin curves were separated. There was no evidence of a legacy effect or a mortality benefit with intensive glucose control. (Funded by the VA Cooperative Studies Program; VADT ClinicalTrials.gov number, NCT00032487.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Reaven PD, Emanuele NV, Wiitala WL, et al. Intensive Glucose Control in Patients with Type 2 Diabetes - 15-Year Follow-up. N Engl J Med. 2019. PMID: 31167051. doi:10.1056/NEJMoa1806802

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。